FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry and medicine and is the use of 3-methyl-8-(piperazin-1-yl)-7-(thietan-3-yl)-1-ethyl-1H-purin-2,6(3H,7H)-dione of hydrochloride as an agent for the treatment and prevention of thrombosis by blocking the platelet receptor GP IIb-IIIa.
EFFECT: invention provides an expansion of the arsenal of agents having therapeutic and prophylactic activities for thrombosis by blocking the platelet receptor GP IIb-IIIa.
1 cl, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS SHOWING ANTITHROMBOTIC EFFECT BY BLOCKING GP IIb-IIIa PLATELETS RECEPTORS (VERSIONS) | 2016 |
|
RU2643336C1 |
| HYDROCHLORIDES OF 1-ALKYL-3-METHYL-8-PIPERAZINO-7-(TIETHANYL-3)XANTHINE SHOWING ANTITHROMBOTIC EFFECT BY BLOCKING GP IIb-IIIa PLATELETS RECEPTORS | 2017 |
|
RU2640579C1 |
| METHOD FOR MODELLING PULMONARY EMBOLISM IN RATS | 2015 |
|
RU2610212C1 |
| AGENT WITH ANTIAGGREGATORY ACTIVITY AND METHOD FOR PRODUCTION THEREOF | 2021 |
|
RU2778686C1 |
| ANTITHROMBOTIC PREPARATION AND METHOD OF PROPHYLAXIS AND TREATMENT OF THROMBOSIS | 2002 |
|
RU2205027C1 |
| METHOD FOR THROMBOCYTE INTRAVASCULAR ACTIVATION ANALYSIS | 2009 |
|
RU2416796C1 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTIAGGREGANT ACTIVITY | 2019 |
|
RU2709017C1 |
| METHOD OF ASSESSING THE EFFICIENCY OF ANTI-CLEGGANT MEDICINAL PRODUCT IN WHOLE PERIPHERAL BLOOD SAMPLES | 2022 |
|
RU2800671C1 |
| TRIAZOLE DERIVATIVES EXHIBITING ANTIAGGREGATORY ACTIVITY | 2021 |
|
RU2770405C1 |
| METHOD OF EVALUATING THE EFFECTIVENESS OF NON-AGGREGATE PREPARATIONS AFFECTING THE METABOLISM OF ARACHIDONIC ACID BY INHIBITION OF CYCLOOXYGENASE-1 BOTH INDIVIDUALLY AND JOINTLY WITH ADP P2Y RECEPTOR ANTAGONIST ON PLATELET MEMBRANES OF THE BLOOD TO THE PATIENT RECEIVING NON-AGGREGATE PREPARATIONS | 2010 |
|
RU2442167C1 |
